CBD is a popular activator of TRPV2 receptors, but THC is looked upon as probably the most strong cannabinoid on this goal. The clinical significance of THC’s conversation with TRPV2 continues to be a spotlight of investigation. Marinol (dronabinol) can be a cannabis-derived medication